New blood test aims to cut unnecessary prostate biopsies
NCT ID NCT07454603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new blood test called PROSTest to see if it can accurately detect prostate cancer in men with high PSA levels. Researchers will compare the test results with standard prostate biopsy findings in 1,500 men. If the test works well, it could help many men avoid the discomfort and risks of an unnecessary biopsy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PROSTest blood test
- What this could lead to
- If successful, this blood test could help many men avoid unnecessary prostate biopsies by more accurately identifying who truly has prostate cancer.
- What could go wrong
- This is an early observational study, not a treatment trial. The test may not be accurate enough to replace current methods, and results need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wren Laboratories
Branford, Connecticut, 06405, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A sharper eye on prostate cancer return: PSMA PET vs. MRI
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI may help spot dangerous prostate cancer and spare men from needless biopsies